Table 4 Analysis of the association between plasma Bmi-1 expression levels and disease-free or overall survival in breast cancer patients regarding pathological stages
From: Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients
Disease-free survival | Bmi-1 absence | Bmi-1 presence | Bmi-1 absence | Bmi-1 presence |
|---|---|---|---|---|
Stages I+II | Stages I+II | Stage III | Stage III | |
N = 43 | N = 36 | N = 8 | N = 7 | |
Cumulative survival | ||||
First year | 95.2% (89.3%–100%) | 100% | 85.7% (60.2%–100%) | 71.4% (45.9%–96.8%) |
Second year | 87.9% (78.1%–97.7%) | 96.8% (90.9%–100%) | 85.7% (60.2%–100%) | 42.8% (5.5%–80.1%) |
Third year | 84.9% (73.1%–96.6%) | 91.4% (79.6%–100%) | 85.7% (60.2%–100%) | 28.5% (0%–61.8%) |
Fourth year | 80.2% (66.5%–93.9%) | 91.4% (79.6%–100%) | 57.1% (11.1%–100%) | 28.5% (0%–61.8%) |
56 months | 80.2% (66.5%–93.9%) | 61.1% (12.1%–100%) | 57.1% (11.1%–100%) | 28.5% (0%–61.8%) |
Significance | NS | 0.08 | ||
Overall survival | Bmi-1 absence | Bmi-1 presence | Bmi-1 absence | Bmi-1 presence |
Stages I+II | Stages I+II | Stages III+IV | Stages III+IV | |
N = 43 | N = 36 | N = 8 | N = 9 | |
Cumulative survival | ||||
First year | 97.5% (93.6%–100%) | 100% | 100% | 88.8% (69.2%–100%) |
Second year | 95.1% (89.2%–100%) | 100% | 100% | 55.5% (25.2%–86.8%) |
Third year | 89.9% (80.1%–99.7%) | 100% | 100% | 22.2% (0%–49.6%) |
Fourth year | 89.9% (80.1%–99.7%) | 92.3% (78.6%–100%) | 100% | 22.2% (0%–49.6%) |
56 months | 0% | 92.3% (78.6%–100%) | 0% | 22.2% (0%–49.6%) |
Significance | NS | 0.0032 | ||